1. At a Glance
In a market where most pharma companies pretend to “innovate” by tweaking paracetamol dosages, Sanofi Consumer Healthcare India Ltd (SCHIL) is the rare new entrant that actually split itself off from its own parent—just to sell you Combiflam without a doctor’s prescription. Formed in 2023 after its demerger from Sanofi India, SCHIL is now a ₹10,860 crore behemoth of consumer healthcare dreams, with ₹798 crore in annual sales and a profit after tax of ₹215 crore.
The company’s Q3FY25 results made the markets do a double take: Revenue ₹2,339 million (+46% YoY), PAT ₹629 million (+40% YoY) — not bad for a newly listed OTC player. With a P/E of 50.5x and ROE of 83.8%, SCHIL is apparently so efficient that even accountants whisper “Om Efficiency Namah.”
The Bhagavad Gita says: “Yogastha kuru karmani” — perform your duty with focus, without attachment to the outcome. Sanofi seems to have taken that literally: it quietly detached its consumer business, focused it like a laser beam, and now sells pain relief, allergy fixes, and vitamin D like enlightenment in blister packs.
At ₹4,692 per share, Sanofi Consumer’s market value screams “premium,” while the stock’s Book Value of ₹112 and Price-to-Book of 42x whisper “calm down, yogi.”
2. Introduction
When a 100-year-old French pharma giant decides to hand its “mass market” business to an Indian spin-off, you know something interesting is cooking. Sanofi India, tired of juggling both insulin and ibuprofen, decided in 2023 to carve out its consumer healthcare division into a separate listed company—Sanofi Consumer Healthcare India Ltd (SCHIL).
Think of it as Sanofi saying: “Let the prescription business stay boring, and let’s give the OTC unit some influencer-style freedom.”
The company now focuses entirely on over-the-counter (OTC) medicines and self-care products: Combiflam, Allegra, Avil, and DePura — household names that sit in Indian kitchen cabinets right next to turmeric and vapor rub.
The demerger was followed by a flashy listing in September 2024. Since then, the stock has been volatile — much like the mood of anyone with a cold trying to decide between Allegra and Avil. Over the past six months, the stock is down 6.35%, and in the last quarter alone, it slipped 10.7%. But with ROCE of 111% and zero pledges, investors still sleep peacefully — probably after popping a Combiflam.
So, does SCHIL have what it takes to dominate the ₹25,000 crore Indian OTC market? Or will it end up as another demerged darling that burns bright for one listing season and then fades like a forgotten vitamin supplement?
Let’s find out.
3. Business Model – WTF Do They Even Do?
Sanofi Consumer Healthcare India Ltd is basically the cool, self-sufficient teenager that broke off from its pharma parent to focus on self-care. Its motto: “If you can buy it without a prescription, it’s probably ours.”
The company’s core business revolves around OTC pharmaceuticals — products you can purchase directly from a chemist or e-commerce site. It operates across pain relief (Combiflam), allergy management (Allegra, Avil), and vitamin and wellness (DePURA). Together, these brands contribute the majority of its ₹798 crore topline.
SCHIL has built a hybrid distribution network: wholesalers, pharmacy chains, hospitals, and even e-commerce channels (because yes, Indians now buy Allegra online while doomscrolling). It works with multiple third-party manufacturers, ensuring scalability without the headache of running too many factories.
With a 91% domestic revenue share and 9% exports, SCHIL has presence across 29 Indian states and a few overseas markets.
Market shares? Pretty neat:
- Allegra – 8.2% in allergy
